)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
MAIA Biotechnology
MAIA Biotechnology (MAIA) investor relations material
MAIA Biotechnology Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary21 Aug, 2026
Company overview and business model
Clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, with lead asset ateganosine (THIO) targeting telomere biology and immunogenicity.
Initial focus is on Non-Small Cell Lung Cancer (NSCLC), with additional trials planned for hepatocellular carcinoma, colorectal cancer, and small cell lung cancer.
Operations based in Chicago, with subsidiaries in Australia and Romania to support clinical and preclinical activities.
Strategic collaborations with Regeneron, BeOne Medicines, and Roche for clinical supply and combination studies.
Financial performance and metrics
Incorporated in 2018; has incurred losses since inception and expects increasing losses as clinical development progresses.
Requires additional capital to fund operations and clinical trials; future financing needs are significant.
Use of proceeds and capital allocation
Net proceeds from securities sales will be used for general working capital and potentially for acquisitions of complementary businesses or technologies.
Management retains broad discretion over allocation of proceeds, with no specific commitments as of the filing date.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MAIA Biotechnology
- Ateganosine (THIO) delivers unprecedented efficacy in late-stage cancer trials, targeting major global markets.MAIA
Investor presentation - Advanced Phase 3 NSCLC trial, raised $33M, and reported a $14.3M net loss for H1 2026.MAIAQ2 2026
- Directors elected and auditors ratified, with 61.88% shareholder participation.MAIAAGM 2026
- Disclosure updates compensation to the CEO's brother and confirms proxy voting procedures.MAIAProxy filing
- $33M equity raise boosts cash to $34.4M, funding Phase 3 NSCLC trial; net loss rises to $6.37M.MAIAQ1 2026
- Proxy statement amended to disclose equity compensation plan details and available shares.MAIAProxy filing
- Election of directors and auditor ratification headline the 2026 virtual annual meeting.MAIAProxy filing
- Virtual meeting to elect directors and ratify auditor, with strong governance and director alignment.MAIAProxy filing
- Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones.MAIAQ4 2025
Next MAIA Biotechnology earnings date
Q3 20266 Nov, 2026
MAIA Biotechnology
Next MAIA Biotechnology earnings date
Q3 20266 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage